# Clinical Trial Landscape: 12_elderly_cll_poor_performance

*Generated: 2026-01-05 18:33:06*

## Summary

- **Total Trials**: 64
- **Flagged for Review**: 0
- **Search Terms Used**: 12

## Phase Distribution

| Phase | Count | Distribution |
|-------|-------|--------------|
| Phase 2 | 19 | █████ 29.7% |
| Phase 1 | 17 | █████ 26.6% |
| Unknown | 11 | ███ 17.2% |
| Phase 3 | 5 | █ 7.8% |
| Not Applicable | 5 | █ 7.8% |
| Phase 1/Phase 2 | 4 | █ 6.2% |
| Phase 4 | 2 |  3.1% |
| Early Phase 1 | 1 |  1.6% |

## Status Distribution

- **Recruiting**: 61 (95.3%)
- **Not yet recruiting**: 2 (3.1%)
- **Enrolling by invitation**: 1 (1.6%)

## Top Sponsors

| Sponsor | Trial Count |
|---------|-------------|
| City of Hope Medical Center | 5 |
| Texas A&M University | 4 |
| M.D. Anderson Cancer Center | 3 |
| National Heart, Lung, and Blood Institute (NHLBI) | 3 |
| Dana-Farber Cancer Institute | 2 |
| Fred Hutchinson Cancer Center | 2 |
| University of Chicago | 2 |
| Nurix Therapeutics, Inc. | 2 |
| University of Utah | 2 |
| Loxo Oncology, Inc. | 2 |
| Mayo Clinic | 2 |
| UNC Lineberger Comprehensive Cancer Center | 1 |
| Wake Forest University Health Sciences | 1 |
| Stryker Instruments | 1 |
| Juno Therapeutics, a Subsidiary of Celgene | 1 |

## Interventions

| Intervention | Occurrences |
|--------------|-------------|
| Biospecimen Collection | 11 |
| Cyclophosphamide | 8 |
| Bone Marrow Biopsy | 8 |
| Computed Tomography | 7 |
| Fludarabine | 6 |
| Venetoclax | 5 |
| Positron Emission Tomography | 5 |
| Mycophenolate Mofetil | 4 |
| Bone Marrow Aspiration | 4 |
| Rituximab | 4 |
| Pirtobrutinib | 4 |
| Methotrexate | 3 |
| Ponatinib | 3 |
| Acalabrutinib | 3 |
| Vincristine | 3 |
| Placebo | 3 |
| Ibrutinib | 3 |
| Zanubrutinib | 3 |
| Echocardiography | 3 |
| Pembrolizumab | 2 |

## Geographic Distribution

| Country | Trial Count |
|---------|-------------|
| United States | 64 |
| Poland | 9 |
| Italy | 7 |
| Canada | 6 |
| France | 6 |
| Spain | 6 |
| United Kingdom | 6 |
| Australia | 6 |
| Czechia | 5 |
| Germany | 4 |
| Hungary | 4 |
| Japan | 4 |
| South Korea | 4 |
| Turkey (Türkiye) | 4 |
| Belgium | 3 |

## Search Term Provenance

| Term | Source | Confidence |
|------|--------|------------|
| TP53 deletion | manual | 1.0 |
| TP53deletion | manual | 0.9 |
| TP53-deletion | manual | 0.9 |
| IGHV unmutated | manual | 1.0 |
| IGHVunmutated | manual | 0.9 |
| IGHV-unmutated | manual | 0.9 |
| chronic lymphocytic leukemia | manual | 1.0 |
| TP53 deletion chronic lymphocytic leukemia | manual | 1.0 |
| IGHV unmutated chronic lymphocytic leukemia | manual | 1.0 |
| TP53 deletion CLL | llm | 0.9 |
| CLL | llm | 0.8 |
| del(17p) | llm | 0.9 |

## All Trials

| NCT ID | Phase | Status | Sponsor | Title |
|--------|-------|--------|---------|-------|
| [NCT06863402](https://clinicaltrials.gov/study/NCT06863402) | Phase 2 | Recruiting | Roswell Park Cancer ... | Nemtabrutinib and Pembrolizumab in ... |
| [NCT07285668](https://clinicaltrials.gov/study/NCT07285668) | Not Applicable | Not yet recruiting | University of Wiscon... | Phase I Study of Prophylactic TCRαβ... |
| [NCT06712810](https://clinicaltrials.gov/study/NCT06712810) | Phase 1 | Recruiting | Mayo Clinic | MC220806: Phase I Study Evaluating ... |
| [NCT06735664](https://clinicaltrials.gov/study/NCT06735664) | Phase 1 | Recruiting | City of Hope Medical... | A Phase I Study of Covalent BTK Inh... |
| [NCT06676033](https://clinicaltrials.gov/study/NCT06676033) | Phase 1 | Recruiting | National Heart, Lung... | Correlative Study of Epcoritamab in... |
| [NCT07030400](https://clinicaltrials.gov/study/NCT07030400) | N/A | Recruiting | H. Lee Moffitt Cance... | Predictors of Health-Related Qualit... |
| [NCT06839053](https://clinicaltrials.gov/study/NCT06839053) | Phase 2 | Recruiting | Fred Hutchinson Canc... | Escalated Inpatient Ramp-Up of Sonr... |
| [NCT06876662](https://clinicaltrials.gov/study/NCT06876662) | Phase 4 | Recruiting | Eli Lilly and Compan... | Long-Term Safety of Pirtobrutinib i... |
| [NCT06846671](https://clinicaltrials.gov/study/NCT06846671) | Phase 3 | Recruiting | BeOne Medicines | A Phase 3, Open-Label, Randomized S... |
| [NCT06972264](https://clinicaltrials.gov/study/NCT06972264) | Phase 3 | Recruiting | Veradermics, Inc. | A Randomized, Double-Blind, Placebo... |
| [NCT06636175](https://clinicaltrials.gov/study/NCT06636175) | Early Phase 1 | Recruiting | Washington Universit... | Early Phase I Evaluation of 64Cu-LL... |
| [NCT06823167](https://clinicaltrials.gov/study/NCT06823167) | Phase 1 | Recruiting | Immunome, Inc. | A Phase 1 Study of IM-1021 in Parti... |
| [NCT06680661](https://clinicaltrials.gov/study/NCT06680661) | Phase 2 | Recruiting | Leland Metheny | ABBA CORD: Double Umbilical Cord Bl... |
| [NCT06788639](https://clinicaltrials.gov/study/NCT06788639) | N/A | Recruiting | Juno Therapeutics, I... | Non-interventional Cohort Study of ... |
| [NCT06588478](https://clinicaltrials.gov/study/NCT06588478) | Phase 2 | Recruiting | Loxo Oncology, Inc. | A Phase 2, Open-Label, Randomized S... |
| [NCT06575296](https://clinicaltrials.gov/study/NCT06575296) | Phase 1 | Recruiting | City of Hope Medical... | A Phase I Study of SNDX 5613 (Revum... |
| [NCT06466122](https://clinicaltrials.gov/study/NCT06466122) | Phase 2 | Recruiting | Kerry Rogers | Phase 2 Study of Combination Pirtob... |
| [NCT06207123](https://clinicaltrials.gov/study/NCT06207123) | Phase 1/Phase 2 | Recruiting | University of Chicag... | A Phase I/II Study to Investigate t... |
| [NCT06059391](https://clinicaltrials.gov/study/NCT06059391) | Phase 2 | Recruiting | City of Hope Medical... | Placebo-Controlled and Randomized P... |
| [NCT05899543](https://clinicaltrials.gov/study/NCT05899543) | N/A | Not yet recruiting | Power Life Sciences ... | Exploring Patient Experiences of In... |
| [NCT05963074](https://clinicaltrials.gov/study/NCT05963074) | Phase 2 | Recruiting | Janssen Research & D... | Multicohort Study to Customize Ibru... |
| [NCT05959434](https://clinicaltrials.gov/study/NCT05959434) | Phase 2 | Recruiting | Texas A&M University | Integration of Cognitive Processing... |
| [NCT06227026](https://clinicaltrials.gov/study/NCT06227026) | Phase 1 | Recruiting | University of Utah | Pilot Study of Anti-CD19 Chimeric A... |
| [NCT06211413](https://clinicaltrials.gov/study/NCT06211413) | N/A | Enrolling by invitation | Abramson Cancer Cent... | A Prospective Longitudinal Cohort S... |
| [NCT06102330](https://clinicaltrials.gov/study/NCT06102330) | Not Applicable | Recruiting | Johns Hopkins Univer... | Multicenter HomeVENT: Home Values a... |
| [NCT06628349](https://clinicaltrials.gov/study/NCT06628349) | Not Applicable | Recruiting | Texas A&M University | Prandial Metabolic Phenotyping in S... |
| [NCT06136559](https://clinicaltrials.gov/study/NCT06136559) | Phase 3 | Recruiting | Merck Sharp & Dohme ... | A Phase 3, Randomized Study to Comp... |
| [NCT05702853](https://clinicaltrials.gov/study/NCT05702853) | Phase 1/Phase 2 | Recruiting | Medical University o... | A Phase 1b Dose Escalation Study of... |
| [NCT05602363](https://clinicaltrials.gov/study/NCT05602363) | Phase 1 | Recruiting | Carna Biosciences, I... | A Phase 1b Study of Oral AS-1763 in... |
| [NCT05672355](https://clinicaltrials.gov/study/NCT05672355) | Phase 2 | Recruiting | City of Hope Medical... | Randomized Observer-Blinded Phase 2... |
| [NCT05873712](https://clinicaltrials.gov/study/NCT05873712) | Phase 2 | Recruiting | Aseel Alsouqi | A Phase II Study Evaluating the Saf... |
| [NCT05780034](https://clinicaltrials.gov/study/NCT05780034) | Phase 1 | Recruiting | Accutar Biotechnolog... | A Phase I Clinical Study to Evaluat... |
| [NCT05879133](https://clinicaltrials.gov/study/NCT05879133) | Not Applicable | Recruiting | M.D. Anderson Cancer... | HEALTH4CLL2: A Randomized Waitlist ... |
| [NCT05805605](https://clinicaltrials.gov/study/NCT05805605) | Phase 2 | Recruiting | Masonic Cancer Cente... | Allogeneic Hematopoietic Stem Cell ... |
| [NCT05544019](https://clinicaltrials.gov/study/NCT05544019) | Phase 1 | Recruiting | Schrödinger, Inc. | A Phase 1, Open-Label, Multicenter,... |
| [NCT05724121](https://clinicaltrials.gov/study/NCT05724121) | N/A | Recruiting | National Heart, Lung... | Observational Study of Cardiac Arrh... |
| [NCT05645107](https://clinicaltrials.gov/study/NCT05645107) | Phase 3 | Recruiting | Grifols Therapeutics... | A Randomized, Multi-Center, Paralle... |
| [NCT05170399](https://clinicaltrials.gov/study/NCT05170399) | Phase 4 | Recruiting | National Heart, Lung... | Vaccine Responses in Patients With ... |
| [NCT05336812](https://clinicaltrials.gov/study/NCT05336812) | Phase 2 | Recruiting | Ohio State Universit... | Prospective Randomized Phase II Stu... |
| [NCT05254743](https://clinicaltrials.gov/study/NCT05254743) | Phase 3 | Recruiting | Loxo Oncology, Inc. | A Phase 3 Open-Label, Randomized St... |
| [NCT05400733](https://clinicaltrials.gov/study/NCT05400733) | Not Applicable | Recruiting | Texas A&M University | Prandial Metabolic Phenotype in Adu... |
| [NCT05131022](https://clinicaltrials.gov/study/NCT05131022) | Phase 1 | Recruiting | Nurix Therapeutics, ... | A Phase 1, Dose Escalation, and Coh... |
| [NCT05279300](https://clinicaltrials.gov/study/NCT05279300) | Phase 1 | Recruiting | CStone Pharmaceutica... | A Phase I, Dose-Escalation and Dose... |
| [NCT05240885](https://clinicaltrials.gov/study/NCT05240885) | N/A | Recruiting | Texas A&M University | Metabolic and Functional Consequenc... |
| [NCT04844528](https://clinicaltrials.gov/study/NCT04844528) | Phase 2 | Recruiting | University of Utah | Randomized Phase 2 Studying the Eff... |
| [NCT05031897](https://clinicaltrials.gov/study/NCT05031897) | Phase 2 | Recruiting | Thomas Jefferson Uni... | A 2 Step Approach to Haploidentical... |
| [NCT04679012](https://clinicaltrials.gov/study/NCT04679012) | Phase 2 | Recruiting | Weill Medical Colleg... | Phase II Study of Polatuzumab Vedot... |
| [NCT03219450](https://clinicaltrials.gov/study/NCT03219450) | Phase 1 | Recruiting | Dana-Farber Cancer I... | A Pilot Study of a Personalized Neo... |
| [NCT04690595](https://clinicaltrials.gov/study/NCT04690595) | Phase 1 | Recruiting | PeproMene Bio, Inc. | A Phase 1 Study Evaluating BAFFR-ta... |
| [NCT04830137](https://clinicaltrials.gov/study/NCT04830137) | Phase 1 | Recruiting | Nurix Therapeutics, ... | A Phase 1, Dose Escalation, Safety ... |

*... and 14 more trials (see trials.csv for full list)*
